Current status and future perspectives of daptomycin development
10.16438/j.0513-4870.2018-0096
- VernacularTitle:新型环脂肽抗生素达托霉素研究进展
- Author:
Xi-xi PENG
1
;
Sai-sai WANG
1
;
Chen FU
1
;
Chang-hua HU
1
;
Guo-jian LIAO
1
Author Information
1. Institute of Modern Biopharmaceuticals, School of Pharmaceutical Sciences, Southwest University, Chongqing 400716, China
- Publication Type:SPECIAL REPORTS
- Keywords:
lipopeptide;
daptomycin;
spectrum of antimicrobial activity;
mode of action;
mechanism of drug resistance;
structure-activity relationship
- From:
Acta Pharmaceutica Sinica
2018;53(6):839-844
- CountryChina
- Language:Chinese
-
Abstract:
Due to the potent bactericidal activity and low incidence of drug resistance, the novel cyclic lipopeptide antibiotic - daptomycin has emerged as one of the first line antimicrobial agents in the treatment of serious infections caused by gram-positive resistant pathogens. This review summarizes the research advances of daptomycin in recent years, mainly including spectrum of antimicrobial activity, biosynthesis, mode of action, mechanism of drug resistance, structure-activity relationships, surotomycin and siderophore-daptomycin conjugate to kill multidrug resistant Acinetobacter baumannii. The findings summarized in this review highlight the directions of next-generation of daptomycin derivatives.
